tmc647055
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01202825)
Timeline
Indications
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 27-cyclohexyl-12,13,16,17-tetrahydro-22-methoxy-11,17-dimethyl-10,10-dioxide-2,19-methano-3,7:4,1-dimetheno-1h,11h-14,10,2,9,11,17-benzoxathiatetraazacyclo docosine-8,18(9h,15h)-dione
- tmc647055
- tmc647055
- tmc647055
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02064842 | Phase 1 | Feb 1, 2014 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01907724 | Phase 1 | May 1, 2013 | Johnson and Johnson, Merck |
| NCT01852604 | Phase 2 | Mar 1, 2013 | Johnson and Johnson, Merck |
| NCT01724086 | Phase 2 | Oct 1, 2012 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01582035 | Phase 1 | Apr 1, 2012 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01202825 | Phase 1 | Apr 1, 2010 | Tibotec |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 5 | 3 | 2 | 2012 |
| Janssen Pharmaceutica NV | For profit | 3 | 0 | 2 | 2012 |
| Merck | For profit | 2 | 2 | 2 | 2013 |
| Tibotec | For profit | 1 | 1 | 1 | 2010 |
4 organizations
Page 1 / 1